Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GrifolsGRFS +0.13%82 Days Sales Outstanding is 37.79 as of Jun. 2026, which is 23% above its 10-year median of 30.76. GuruFocus rates GRFS with a GF Score™ of 82/100 and a GF Value™ of $8.61 (Fairly Valued). The stock has 7 warning signs investors should review. Among 945 Drug Manufacturers companies, Grifols ranks better than 83.81% on this metric.
Grifols's average Accounts Receivable for the
three
months ended in Jun. 2026 was $894 Mil. Grifols's Revenue for the
three
months ended in Jun. 2026 was $2,159 Mil.
Hence, Grifols's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 37.79.
The historical rank and industry rank for Grifols's Days Sales Outstanding or its related term are showing as below:
GRFS'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.59 Med: 30.76 Max: 38.85
Current: 38.85
During the past 13 years, Grifols's highest Days Sales Outstanding was 38.85. The lowest was 22.59. And the median was 30.76.
GRFS's Days Sales Outstanding is ranked better than 83.81% of 945
companies
in the Drug Manufacturers industry
Industry Median: 71.76
vs GRFS: 38.85
Grifols's Days Sales Outstanding
increased
from Jun. 2025 (36.14) to Jun. 2026 (37.79).
Grifols (NAS:GRFS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Grifols Days Sales Outstanding Related Terms
Grifols Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Grifols's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRFS vs LLY, JNJ, ABBV: Days Sales Outstanding Comparison
For the Drug Manufacturers - General subindustry, Grifols's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grifols Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grifols's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Grifols's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grifols (GRFS) has a Days Sales Outstanding of 37.79 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Grifols and its competitors. This is 23% above median its historical median of 30.76. Over the past decade, Grifols' Days Sales Outstanding has ranged from 22.59 to 38.85. According to the industry distribution chart, Grifols ranks #153 out of 945 companies in the Drug Manufacturers industry, placing it in the top 16.2%.
Is Grifols' Days Sales Outstanding too high?
Grifols' current Days Sales Outstanding of 37.79 is 23% above median its 10-year median of 30.76. Over the past 10 years, this metric has ranged from a low of 22.59 to a high of 38.85. The Drug Manufacturers industry median Days Sales Outstanding is 71.76. Grifols' value of 37.79 is 47.3% below this industry median. Based on the distribution chart, Grifols ranks #153 out of 945 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Grifols has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Grifols' Days Sales Outstanding compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #153 out of 945 companies for Days Sales Outstanding. This places Grifols in the top 16% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 71.76. Grifols' value of 37.79 is 47.3% below this benchmark. Historically, Grifols' own Days Sales Outstanding has ranged from 22.59 to 38.85 over the past decade. While the company's 10-year median is 30.76 vs. the industry median of 71.76, Grifols has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.76, based on 945 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current Days Sales Outstanding of 37.79 is 47.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Grifols and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current Days Sales Outstanding is 37.79, which is 23% above median its own 10-year median of 30.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Fairly Valued. The stock's GF Value™ is $8.61, compared to a current price of $8.00 — trading 7.1% below its estimated fair value. The current Days Sales Outstanding is 37.79, which is 23% above median its 10-year median of 30.76 and 47.3% below the Drug Manufacturers industry median of 71.76. Grifols' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Grifols (GRFS), the current Days Sales Outstanding is 37.79 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grifols (GRFS) Overvalued in 2026?
Based on GuruFocus' analysis, Grifols stock appears to be undervalued.
The current stock price of $8.00 is trading 7.1% below its estimated GF Value™ of $8.61.
GuruFocus considers Grifols to be Fairly Valued.
Key valuation signals for GRFS:
Days Sales Outstanding: 37.79 (23% above median its 10-year median of 30.76)
GF Value™: $8.61 vs. price of $8.00 (7.1% below fair value)
Industry Position: 47.3% below the Drug Manufacturers median (#153 of 945)
No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
82GF Score
Get the complete analysis for GRFS
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRFS has been successfully added to your 
